CRISPR-based m6A modification and its potential applications in telomerase regulation

Mingliang Yi, Mingyue Wang, Yongjie Xu, Zhikun Cao, Yinghui Ling, Zijun Zhang, Hongguo CaoFrontiers in Cell and Developmental Biology 2023 · DOI

Abstract

Telomerase determines cell lifespan by controlling chromosome stability and cell viability, and m<sup>6</sup>A epigenetic modification plays an important role in the regulation of telomerase activity. Using CRISPR epigenome editing to analyze specific m<sup>6</sup>A modification sites in telomerase provides an important tool for analyzing the molecular mechanism of m<sup>6</sup>A modification regulating telomerase activity. In this review, we clarify the relevant applications of the CRISPR system, paying special attention to the regulation of m<sup>6</sup>A modification in stem cells and cancer cells. We emphasize the regulation of m<sup>6</sup>A modification on telomerase activity, point out that specific m<sup>6</sup>A modification sites regulate telomerase activity, and discuss strategies based on telomerase activity and disease treatment, which are helpful to promote research into anti-aging and tumor-related diseases.

Introduction: The Telomerase Paradox

Telomerase is often described as a double-edged sword: it is the "fountain of youth" that maintains telomere length to prevent cellular aging, but its overactivation is a hallmark of over 90% of cancers. Understanding how telomerase is regulated is critical for both regenerative medicine and oncology, yet traditional methods have struggled with the necessary precision.

The focus of current research is shifting toward m<sup>6</sup>A (N6-methyladenosine), the most prevalent internal modification in eukaryotic mRNA. While "writers" (like METTL3) and "erasers" (like ALKBH5) are known to influence telomerase, traditional knockdown studies are "blunt instruments" that affect the entire transcriptome. The challenge addressed here is achieving site-specific manipulation of these RNA modifications to understand their exact role in telomerase assembly and function without altering the underlying DNA sequence.

CRISPR-Based Tools for Epitranscriptome Editing

To address the limitations of traditional methods, researchers have developed a suite of CRISPR-based tools designed for "epigenome" and "epitranscriptome" editing. Unlike standard CRISPR which cuts DNA, these methods utilize nuclease-inactive versions of Cas proteins to target specific sequences without permanent genomic alteration.

Overview of Class I and Class II CRISPR systems and their mechanisms of action.

These tools include:

  • dCas9 and dCas13 (Dead Cas): Nuclease-inactive versions that bind to specific DNA or RNA sequences guided by an sgRNA but do not cleave them.
  • Fusion Proteins (dm<sup>6</sup>ACRISPR): The "dead" Cas proteins are fused to effector domains. For example, dCas13 fused to the m<sup>6</sup>A writer METTL3 can add a methyl group to a specific RNA site, while fusion to ALKBH5 or FTO can remove it.
  • The "Tage" System: A specialized CRISPR activation (CRISPRa) system using dCas9-VP64 to target telomerase-related genes, effectively creating a "cancer gene therapy" that can induce cell death in malignant cells.
  • Base Editors (CBE/ABE): Used to correct or introduce specific point mutations in the TERT promoter region, which is frequently mutated in clinical cancer cases.

Targeted Manipulation of the m<sup>6</sup>A Cycle

The m<sup>6</sup>A modification is a dynamic process involving writers, readers, and erasers. CRISPR-based systems allow for the precise targeting of these components to specific transcripts, enabling a granular understanding of telomerase regulation.

The m<sup>6</sup>A methylation cycle and its targeted manipulation using dCas9 and dCas13 fusion complexes.

Key insights from these targeted approaches include:

  • Spatial Regulation of Telomerase: m<sup>6</sup>A acts as a traffic controller. For instance, m<sup>6</sup>A modifications on the telomerase RNA component (hTR) are essential for its proper assembly with the TERT protein in the nucleolus. Removing these marks via CRISPR-based erasers leads to assembly failure.
  • m<sup>6</sup>A as a Stability Switch: m<sup>6</sup>A readers (like the YTH family) can either stabilize TERT mRNA or accelerate its decay depending on the specific site modified, suggesting that the location of the modification is as important as the modification itself.
  • Reversibility: Unlike DNA editing, CRISPR-mediated m<sup>6</sup>A editing is potentially reversible and does not cause permanent genomic changes, making it a "softer" and potentially safer therapeutic approach.

Key Results and Therapeutic Potential

The review synthesizes findings from large-scale resources, including the Pan-Cancer Analysis of Whole Genomes (PCAWG) and clinical data regarding TERT promoter mutations. Landmark quantitative findings include:

  • METTL3-HMBOX1 Axis: Precise methylation of HMBOX1 mRNA via CRISPR tools was shown to regulate telomerase recruitment; its downregulation leads to significant telomere loss in cancer cells.
  • ALKBH5 Impact: Overexpression of the ALKBH5 eraser via CRISPR-dCas9 reduced the assembly efficiency of telomerase components (TCAB1 and DKC1), effectively inhibiting telomerase activity in targeted cells.
  • Anti-tumor Strategies: The "Tage" system has demonstrated the ability to effectively kill cancer cells in vivo by targeting the telomere repeat sequence, providing a proof-of-concept for CRISPR-based anti-tumor strategies.

Challenges and Future Directions

Despite the promise of CRISPR-based epitranscriptome editing, several hurdles remain for clinical translation:

  • Off-Target Effects: While dCas systems don't cut DNA, they can still bind to non-target RNA/DNA sequences, potentially disrupting other vital cellular processes.
  • The p53 Hurdle: Introducing CRISPR/Cas9 machinery can inadvertently trigger the p53 DNA damage response, leading to cell cycle arrest or apoptosis.
  • Delivery Systems: Efficiently delivering these large CRISPR-effector complexes into specific tissues (e.g., via AAV or lentivirus) remains a major hurdle.
  • Expanding the Toolkit: Future work should expand CRISPR tools to target other marks like m<sup>1</sup>A and m<sup>5</sup>C, which likely also play roles in telomerase regulation.

Long-term safety research is needed to determine if persistent epitranscriptome editing leads to cellular "exhaustion" or unforeseen compensatory mutations.

Summary updated

Abstract

Telomerase determines cell lifespan by controlling chromosome stability and cell viability, m<sup>6</sup>A epigenetic modification plays an important role in the regulation of telomerase activity. Using CRISPR epigenome editing to analyze specific m<sup>6</sup>A modification sites in telomerase will provide an important tool for analyzing the molecular mechanism of m<sup>6</sup>A modification regulating telomerase activity. In this review, we clarified the relevant applications of CRISPR system, paid special attention to the regulation of m<sup>6</sup>A modification in stem cells and cancer cells based on CRISPR system, emphasized the regulation of m<sup>6</sup>A modification on telomerase activity, pointed out that m<sup>6</sup>A modification sites regulate telomerase activity, and discussed strategies based on telomerase activity and disease treatment, which are helpful to promote the research of anti-aging and tumor related diseases.
BibTeX
@inproceedings{yi2023crispr,
  author = {Mingliang Yi and Mingyue Wang and Yongjie Xu and Zhikun Cao and Yinghui Ling and Zijun Zhang and Hongguo Cao},
  title = {{CRISPR-based m6A modification and its potential applications in telomerase regulation}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  doi = {10.3389/fcell.2023.1200734},
}
Figure